Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)

Market Cap	4.12B -35.9%
Revenue (ttm)	59.56M -65.6%
Net Income	-162.45M
EPS	-0.21
Shares Out	783.29M
PE Ratio	n/a
Forward PE	8.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,549,357
Open	5.49
Previous Close	5.30
Day's Range	5.04 - 5.49
52-Week Range	3.98 - 11.80
Beta	0.30
Analysts	Buy
Price Target	9.89 (+87.84%)
Earnings Date	Aug 24, 2026

About HKG:1167

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People’s Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhibitor that is in a Phase IIa trial for solid tumors and hematologic mal...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 67
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1167

Financial Performance

In 2025, HKG:1167's revenue was 53.53 million, a decrease of -65.62% compared to the previous year's 155.71 million. Losses were -145.98 million, -6.25% less than in 2024.

Financial numbers in CNY

Analyst Summary

According to 2 analysts, the average rating for 1167 stock is "Buy." The 12-month stock price target is $9.89, which is an increase of 87.84% from the latest price.

Price Target

$9.89

(87.84% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 21, 2026

Data Sources Report a data error